Please assess the completion status of the following clinical trial:

Trial Title: Narrowband UVB Phototherapy in the Treatment of Psoriasis Vulgaris

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Signed informed consent.~* History of chronic plaque psoriasis vulgaris, for at least six months.~* ≥10% body surface affected~* Age 18 or greater.~* Concomitant, chronic, but well-controlled medical conditions such as hypertension are allowable.~* No treatment with topical steroids for at least 2 weeks prior to entering the study~* No treatment with systemic therapies, including etretinate, UVB, PUVA, or cyclosporine, other biologics 4 weeks prior to entering the study. However, if a patient is considered to be unstable, or would deteriorate clinically if the systemic agent is ceased (eg efalizumab), a shorter washout period may be considered, and would be documented in the patient charts.~* Patients who receive a stable dose of methotrexate (defined as \<15mg/week for 4 months or greater) for psoriatic arthritis may be included.~Exclusion Criteria:~* Subjects who do not meet the above criteria, or who meet any of the following criteria:~  * Guttate, erythrodermic, or pustular psoriasis as sole or predominant form of psoriasis.~ * PHOTOSENSITIVITY: Hypersensitivity to sunlight or UVB light of any type; history of Lupus, PMLE, or any disease known to be worsened by UV light exposure~ * A history of non-melanoma skin cancer may be acceptable, and in this situation, the patient will be carefully evaluated.~ * Poorly controlled medical conditions of any kind.~ * Any medical condition that, in the opinion of the Investigator, would jeopardize the health or well being of the patient during the course of this study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- NB-UVB (Type: OTHER): Regular, monitored NB-UVB treatment. Patients will be treated 3 times per week, and a full course of therapy is 12 weeks. NB-UVB dosing is increased by 5-20% increments in exposure time, depending on response of the patient.

Based on this trial design, predict the completion outcome and termination type (if applicable).